Clinical Trial Search

Phase 2 N=67 Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

Inflammatory Breast Cancer · Invasive Ductal Breast Carcinoma · Invasive Lobular Breast Carcinoma

Primary: Number of Participants With Local, Regional, and/or Distant Failure — 12 Participants

Rutgers, The State University of New Jersey Results Apr 2023 1.5% serious AE View details

Phase 2 N=89 Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease

Dry Eye Disease · Dry Eye Syndrome

Primary: Number of Participants With Adverse Events by Severity in Each Cohort — 0; 0; 2; 0 Participants

Senju Pharmaceutical Co., Ltd. Results Apr 2023 0.0% serious AE View details

Phase 2 N=51 Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer

Cognitive Decline · Chemo-brain

Primary: Change in Visual Working Memory - Delayed Matching to Sample Test — 16; 13; 16 Participants

UNC Lineberger Comprehensive Cancer Center Results Apr 2023 0.0% serious AE View details

Phase 2 N=29 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

Hematologic Malignancy

Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants

Medical College of Wisconsin Results Apr 2023 96.6% serious AE View details

Phase 2 N=106 A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Primary: Base Study: Change From Baseline in Pulmonary Vascular Resistance (PVR) at 24 Weeks — -27.6; -168.4; -258.9; 802.0 dynes*sec/cm^5 — p=0.0030

Acceleron Pharma, Inc., a wholly-owned… Results Apr 2023 23.2% serious AE View details

Phase 2 N=1,808 Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain.

Acute Non-cardioembolic Ischemic Stroke

Primary: Efficacy-Number of Participants With Composite of Symptomatic Ischemic Stroke or Covert Brain Infarcts Detected by Magnetic Resonance Imaging (MRI) — 24; 25; 17; 23…

Bayer Results Apr 2023 20.4% serious AE View details

Phase 2 N=30 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Estrogen Receptor Negative · Estrogen Receptor Positive · HER2/Neu Negative

Primary: Number of Participants With Overall Response — 5; 2 Participants

City of Hope Medical Center Results Apr 2023 16.7% serious AE View details

Phase 2 N=109 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery

Inflammation and Pain Following Ocular Surgery

Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) — 10; 12; 11; 27 Participants — p=0.4543

Biogen Results Apr 2023 0.0% serious AE View details

Phase 2 N=15 Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

B-Cell Chronic Lymphocytic Leukemia · B-Lymphocytic Leukemia, Chronic · Chronic Lymphocytic Leukemia

Primary: Number of Participants With Complete Response of the Combination of Ibrutinib, Fludarabine, and Pembrolizumab in Patients With High-risk and/or Relapsed/Refractory…

National Heart, Lung, and Blood Institute (NHLBI) Results Apr 2023 73.3% serious AE View details

Phase 2 N=61 Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Endometrial Cancer

Primary: Progression Free Survival Differences Between Treatment Arms. — 8.049; 12.945 months

Yale University Results Apr 2023 33.3% serious AE View details

Phase 2 N=22 Safety and Efficacy of SLI-F06 in Wound Healing and Scar Appearance

Scars

Primary: Patient and Observer Scar Assessment Scale (POSAS) - PI Assessment — 4.4; 4.5 score on a scale

Scarless Laboratories, Inc. Results Apr 2023 13.6% serious AE View details

Phase 2 N=101 The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

COVID-19

Primary: Number of Participants With Worsening of COVID-19 Within 28 Days — 1; 1 Participants

Pulmotect, Inc. Results Apr 2023 3.0% serious AE View details

Phase 2 N=182 Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)

Post Traumatic Stress Disorder (PTSD) · Addiction · Alcohol Abuse

Primary: Change in Alcohol Use Severity — -3.406; -3.934 standard drinks per day

Medical University of South Carolina Results Apr 2023 4.4% serious AE View details

Phase 2 N=31 Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

HER2/Neu Positive · Recurrent Breast Carcinoma · Stage IV Breast Cancer

Primary: Number of Patients With Grade 3 or Higher Toxicity Per Study Arm. — 2; 0 Participants

University of Washington Results Apr 2023 0.0% serious AE View details

Phase 2 N=195 A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)

Cognitive Impairment Associated With Schizophrenia

Primary: Change From Baseline in Change From Baseline in Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB)…

Biogen Results Apr 2023 2.1% serious AE View details